Squarepoint’s Aura Biosciences AURA Stock Holding History

Squarepoint’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,447	Closed	-$82K	–	4041
2024 Q1	$82K	Buy	+10,447	New	+$86.6K	﹤0.01%	3825

Other funds holding AURA

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Squarepoint's AURA Position: Q2 2024 in Review

Squarepoint sold out of Aura Biosciences (AURA) in Q2 2024, closing a stake of 10,447 shares — an estimated $82K sold.

Squarepoint first reported a position in AURA in Q1 2024 and held it in 1 quarter. The position peaked at $82K in Q1 2024. 75 funds tracked by Wall St. Rank hold AURA as of Q2 2024.

Squarepoint reported no remaining Aura Biosciences position as of Q2 2024 after selling out during the quarter.
Squarepoint sold 10,447 Aura Biosciences shares in Q2 2024, an estimated $82K.
Squarepoint first reported a position in Aura Biosciences in Q1 2024 and held it in 1 quarter.
Squarepoint's Aura Biosciences position peaked at $82K in Q1 2024.
75 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2024.

Based on Squarepoint's 13F filing for Q2 2024, filed 14 Aug 2024.